Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2005
10/18/2005US6955898 Targeting pharmaceutical agents to injured tissues
10/18/2005US6955810 Method for the treatment of inflammatory disorders
10/18/2005CA2366391C Aspartate derivative of amlodipine
10/18/2005CA2340138C 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
10/18/2005CA2334702C Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol
10/18/2005CA2137441C Amino-substituted benzenesulfonylureas and -thioureas, processes for their preparation, and their use as pharmaceuticals
10/18/2005CA2125730C Novel sulfonylamino pyrimidines
10/18/2005CA2046265C Sulphured imadazole derivatives, their preparation process, the new intermediates obtained, their application as drugs and the pharmaceutical preparations containing them
10/18/2005CA2006929C Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs
10/15/2005CA2504255A1 The local administration of a combination of sirolimus and 2-methoxyestradiol for the treatment of vulnerable plaque
10/13/2005WO2005095609A1 Cardioinhibitory/ antihypertensive novel endogenous physiologically active peptide
10/13/2005WO2005095604A1 Rf rp transgenic animal
10/13/2005WO2005095600A1 Heparin-binding protein having heparan sulfate sugar chain attached thereto, process for producing the same and medicinal composition containing the same
10/13/2005WO2005095587A1 Process for producing somatic stem cell differentiated from embryonic stem cell and use of the same
10/13/2005WO2005095452A1 Calcium ion leakage inhibitors
10/13/2005WO2005095438A1 Saponins, the preparation and the use of the same
10/13/2005WO2005095427A1 Composition for prevention or treatment of thrombosis
10/13/2005WO2005095414A1 Adiponectin increasing agent
10/13/2005WO2005095412A1 Antiallergic agent
10/13/2005WO2005095375A1 Extract of sophora flavescens flavonoids and uses thereof
10/13/2005WO2005095373A1 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
10/13/2005WO2005095372A1 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
10/13/2005WO2005095324A1 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease
10/13/2005WO2005094888A1 Damaged tissue therapeutic agent and therapeutic method
10/13/2005WO2005094881A1 Antibody drug
10/13/2005WO2005094866A1 Adiponectin expression inducer and utilization of the same
10/13/2005WO2005094865A1 Compound having angiogenic effect
10/13/2005WO2005094860A1 Agent improving peripheral blood flow
10/13/2005WO2005094858A1 Antidiabetic composition
10/13/2005WO2005046689A3 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
10/13/2005WO2005026741B1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
10/13/2005WO2004062578A3 Methods for reducing mortality associated with acute myocardial infarction
10/13/2005US20050228336 Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
10/13/2005US20050228178 Process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one compounds. and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
10/13/2005US20050228177 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228055 Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof
10/13/2005US20050228039 Luminacin analogs and uses thereof
10/13/2005US20050228036 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
10/13/2005US20050228029 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis
10/13/2005US20050228022 blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants
10/13/2005US20050228018 Chemical compounds
10/13/2005US20050228011 use of carboxy-functional benzofurans or benzothiophenes to treat tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, rheumatoid arthritis, and sickle cell anemia; greater bioavailability or fewer side-effects
10/13/2005US20050228005 Protein kinase inhibitors and uses thereof
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050227997 Selective inhibition of aggrecanase in osteoarthritis treatment
10/13/2005US20050227991 Containing a piperazine ring, e.g., N'-(4-{4-[5-(1,2-dithiolan-3-yl)pentanoyl]-1-piperazinyl)phenyl)-2-thiophenecarboximidamide and intermediates for preparing them; useful for inhibiting NO synthase and regenerating antioxidants
10/13/2005US20050227988 compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety
10/13/2005US20050227986 Vanilloid receptor ligands and their use in treatments
10/13/2005US20050227979 E.g., 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane; these compounds modulate the activity of the histamine receptor, specifically the H3 receptor, without the inherent problems associated with the presence of an imidazolyl moiety
10/13/2005US20050227974 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
10/13/2005US20050227973 Human adam-10 inhibitors
10/13/2005US20050227972 treating disorders of the cardiovascular system; adenosine receptor agonists/antagonists
10/13/2005US20050227957 Therapy for oxidation stresses; complex of drug and enzyme mimetics; lipophilic cation moiety covalently bonded to glutathione peroxidase mimetic moiety is selected from the group consisting of: benzisoselenazolones, diaryl diselenides and diaryl selenides
10/13/2005US20050227951 Verification of translation
10/13/2005US20050227948 Hif hydroxylase inhibitors
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227353 Methods of inducing differentiation of stem cells
10/13/2005US20050227282 Human extracellular matrix-1
10/13/2005US20050227280 Proteases
10/13/2005US20050227249 Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
10/13/2005US20050226877 administration of a function blocking antibody which is capable of binding an epitope of VLA-1; arthritis
10/13/2005US20050226862 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders and for identifying agents therapeutic therefor
10/13/2005US20050226849 Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses
10/13/2005US20050226813 Labelled somatostatin analogs backbone cyclized through metal complexation
10/13/2005DE10120630B4 Verwendung von Bulbophyllum neilgherrense zur Behandlung von Störungen des Herz-Kreislaufsystems Use of Bulbophyllum neilgherrense for the treatment of disorders of the cardiovascular system
10/13/2005CA2562944A1 Adiponectin enhancer
10/13/2005CA2562126A1 Pyrazine derivatives and pharmaceutical use thereof
10/13/2005CA2561732A1 Antibody drug
10/13/2005CA2560011A1 Cospeptin, cosmedin and their uses
10/12/2005EP1584925A1 Novel screening method
10/12/2005EP1583760A2 Substituted heterocyclic compounds
10/12/2005EP1583759A1 Pyridine derivatives useful for inhibiting sodium/calcium exchange system
10/12/2005EP1583754A1 Thiophene derivative ppar modulators
10/12/2005EP1583751A1 Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
10/12/2005EP1583746A1 A pyrazole derivative as ppar modulator
10/12/2005EP1583744A2 Substituted benzylamine derivatives and methods of use
10/12/2005EP1583738A1 Indenoncarboxylic acids derivatives and their use for the treatment of and preventing diabetes and dyslipidaemia
10/12/2005EP1583553A2 Therapeutic use of modulators of notch
10/12/2005EP1583530A1 2-aminothiazole allosteric enhancers of a1-adenosine receptors
10/12/2005EP1583526A1 Acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
10/12/2005EP1494659B1 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt
10/12/2005EP1478362B1 A combination treatment for acute myocardial infarction
10/12/2005EP1448196B1 Benzothiazole derivatives as adenosine receptor ligands
10/12/2005EP1370568B1 Chemical compounds
10/12/2005EP1339867A4 Alterations in the long qt syndrome genes kvlqt1 and scn5a and methods for detecting same
10/12/2005EP1272666B1 A functional assay of high-density lipoprotein
10/12/2005EP1224173B1 Pyrazole derivatives as cannabinoid receptor antagonists
10/12/2005EP1202964B1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
10/12/2005EP1201235B1 Neuropathy improvers containing nitrogenous compounds as the active ingredient
10/12/2005EP1194421B1 Selective npy (y5) antagonists
10/12/2005EP1169322B1 Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
10/12/2005EP1150982B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha
10/12/2005EP1143949B1 19-nor-vitamin d3 compounds with calcemic activity
10/12/2005EP1105104B1 Extended release buccal bioadhesive tablet
10/12/2005EP1049676B1 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
10/12/2005EP1015459B9 Tetrazole-containing rapamycin analogs with shortened half-lives
10/12/2005EP0946170B1 Diclofenac for the treatment of vasculopathies
10/12/2005EP0794774B1 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
10/12/2005CN1681926A Human antihuman MCP-1 antibody and antibody fragment thereof
1 ... 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 ... 1595